Why the study?
Does short-term intravenous or long-term oral amiodarone prevent ventricular fibrillation in a conscious canine model of sudden coronary death?
Does short-term intravenous or long-term oral amiodarone prevent ventricular fibrillation in a conscious canine model of sudden coronary death?
In a canine model of sudden coronary death, both short-term intravenous and long-term oral amiodarone significantly reduced the incidence of ventricular fibrillation, with long-term oral therapy demonstrating greater efficacy and more pronounced QT prolongation.
Answers are grounded in this paper and cite their sources.
Amiodarone shows promise in canine VF models but should not yet alter practice; leaves open translation to human sudden death prevention.
The antifibrillatory properties of short-term intravenous (10 mg/kg/hr) and long-term (10 mg/kg/day for 24 days) oral amiodarone administration were examined in a conscious canine preparation of sudden coronary death. In this preparation, ventricular fibrillation was produced by electrically induced left circumflex intimal injury and thrombosis in the presence of previous anterior myocardial infarction. On day 4 after anterior myocardial infarction animals were assigned to receive short-term intravenous or long-term oral amiodarone treatment. Animals within each group were randomly assigned to control or drug treatment. Neither short-term intravenous nor long-term oral amiodarone treatment prevented the development of ST segment changes or premature ventricular beats, but both short-term intravenous amiodarone and long-term oral amiodarone administration significantly reduced the incidence of ventricular fibrillation (short-term intravenous amiodarone [n = 10], incidence of 60% vs control [n = 10] incidence of 100%, p < .05; long-term oral amiodarone [n = 10], incidence of 20% vs control [n = 11] incidence of 91%, p < .002). Both short-term intravenous and long-term oral amiodarone administration produced increases in the PR and ratecorrected QT intervals. However, prolongation of the corrected QT interval in the group receiving long-term oral amiodarone (61 + 18 msec) was greater than in the group receiving short-term intravenous drug (31 11 msec, p < .05). This discrepancy between effects of long-term oral and short-term intravenous amiodarone could not be based on differences in plasma (1.9 0.2 vs 2.7 + 0.5 gg/ml, respectively) or right ventricular myocardial concentrations (13 + 2 vs 24 + 4 ,g/g, respectively). These data suggest that while both long-term oral amiodarone and short-term intravenous amiodarone prevent ventricular fibrillation in the conscious dog subjected to acute myocardial ischemia in the presence of previous anterior myocardial infarction, long-term oral amiodarone may have an additional electrophysiologic action and therefore greater efficacy.
No takes yet. Share an insight, caveat, or question.
Patterson et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: